You are here

Combination Approaches

Layout option: 
1 Column (equal)
Body: 

Because cancer is not a single disease, our approach to treatment cannot be “one size fits all.” At Pfizer Oncology, we believe that the future lies in novel, biologically rational combinations based on unique tumor characteristics.

We’re looking at multiple mechanisms and pathways that contribute to tumor growth and investigating new technologies to target these pathways to lead a next wave of innovation in immuno-oncology.


UNDERSTANDING HOT AND COLD TUMOR STRATEGIES

Depending on the “temperature” of the tumor, researchers may activate, release the “brakes” on, or sustain the immune response—or use a combination of these approaches. To do this, they rely on different activators and inhibitors. The goal is to move T cells inside the tumor, so the immune system can recognize cancer and mount a strong defense against it.

hot_warm_cold_strategies_infographic102318.jpg

*Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of October 2018.


Magnifying_Glass-50px.png

Searching For The Right Combinations

When looking at our next wave of innovative Oncology medicines, we are focused on delivering compelling value to patients in areas of high unmet need through IO combinations, precision IO approaches, and next-generation IO modalities.

Our approach of combining therapies involve smart sequencing of IO molecules with each other or with targeted or traditional compounds. Pfizer Oncology researchers are exploring novel combination approaches to active IO agents.

 

EXAMPLES OF COMBINATIONS UNDER INVESTIGATION*

Question Pairs: 
Question: 

IO agent + targeted agent

Answer: 
CD20 inhibitor VEGFR PARP inhibitor
Androgen receptor
inhibitor
   

 

Question: 

IO agent + IO agent

Answer: 
PD-1 inhibitor OX40 agonist PD-L1 inhibitor
MCSF inhibitor 4-1BB agonist CTLA-4 inhibitor
Question: 

IO agent + vaccine/oncolytic virus

Answer: 
vaccine-based immunotherapy regimen (VBIR)
oncolytic vaccinia virus
Question: 

IO agent + ADC

Answer: 
anti-PTK-7
Layout option: 
1 Column (equal)
Body: 

Other IO agents under investigation in various combinations

  • Small molecule targeted agents
  • Bispecific antibodies

 

*Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of October 2018.


Find out about Pfizer IO clinical trials

Find Pfizer IO clinical trials that are enrolling patients


Quote / Citation: 
Citations: 

At Pfizer we feel that, by combining immune therapies with our targeted agents, we may be able to help a larger proportion of patients and be more successful.

Author: 
Dimitry Nuylen, MD, PhD Vice President, Immuno-Oncology